"Will imatinib compromise reproductive capacity?," Oncologist (Vol: 16, Issue: 10, Page 1422-1427) - 2011
"Clonal chromosomal abnormalities in CD34+/CD-38 hematopoietic cells from cytogenetically normal chronic myeloid leukemia patients with a complete cytogenetic response to tyrosine kinase inhibitors," Leukemia (Vol: 24, Issue: 8, Page 1525-1528) - 2010
"Epidemiologic study on survival of chronic myeloid leukemia and Ph + acute lymphoblastic leukemia patients with BCR-ABL T315I mutation," Blood (Vol: 114, Issue: 26, Page 5271-5278) - 2009
"Drug plasma monitoring in CML and GIST: A case-based discussion," Clinical Advances in Hematology and Oncology (Vol: 7, Issue: 11, Page ) - 2009
"Imatinib plasma trough levels in the management of CML: Ready for prime time?," Clinical Advances in Hematology and Oncology (Vol: 7, Issue: 11, Page 766-767) - 2009
"Management of Drug Toxicities in Chronic Myeloid Leukaemia," Best Practice and Research: Clinical Haematology (Vol: 22, Issue: 3, Page 409-429) - 2009
"Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia," Cancer Control (Vol: 16, Issue: 2, Page 108-121) - 2009
"Appropriate sequencing of tyrosine kinase inhibitors in chronic myelogenous leukemia: When to change? a perspective in 2009," Current Opinion in Hematology (Vol: 16, Issue: 2, Page 135-139) - 2009
"Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib," Blood (Vol: 114, Issue: 13, Page 2598-2605) - 2009
"Response dynamics in chronic-phase chronic myeloid leukemia," Clinical Lymphoma and Myeloma (Vol: 9, Issue: 3, Page 217-222) - 2009
"An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy," Journal of Molecular Diagnostics (Vol: 10, Issue: 2, Page 177-180) - 2008
"Optimizing Outcomes for Patients With Advanced Disease in Chronic Myelogenous Leukemia," Seminars in Oncology (Vol: 35, Issue: SUPPL. 1, Page S1-S17) - 2008
"An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia," Leukemia (Vol: 22, Issue: 12, Page 2269-2272) - 2008
"A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response," Clinical Cancer Research (Vol: 13, Issue: 20, Page 6136-6143) - 2007
"Mutational analysis and overcoming imatinib resistance in chronic myeloid leukemia with novel tyrosine kinase inhibitors," Current Treatment Options in Oncology (Vol: 8, Issue: 4, Page 287-295) - 2007
"Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib," Leukemia (Vol: 21, Issue: 3, Page 489-493) - 2007
"BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML," Blood (Vol: 107, Issue: 11, Page 4250-4256) - 2006
"Stem cell transplantation in patients with chronic myelogenous leukemia: When should it be used?," Mayo Clinic Proceedings (Vol: 81, Issue: 3, Page 404-416) - 2006
"Chronic myeloid leukemia in 2006: A perspective," Haematologica (Vol: 91, Issue: 2, Page 152-158) - 2006
"Defining and managing imatinib resistance.," Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program (Vol: , Issue: , Page 219-225) - 2006
